Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Stake Raised by Algert Global LLC

Algert Global LLC lifted its stake in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 141.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 89,536 shares of the medical device company's stock after purchasing an additional 52,423 shares during the quarter. Algert Global LLC owned about 0.14% of Tandem Diabetes Care worth $3,225,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Vanguard Group Inc. grew its stake in Tandem Diabetes Care by 1.1% in the 4th quarter. Vanguard Group Inc. now owns 7,440,005 shares of the medical device company's stock valued at $267,989,000 after acquiring an additional 77,451 shares during the last quarter. ArrowMark Colorado Holdings LLC grew its stake in Tandem Diabetes Care by 14.1% in the 4th quarter. ArrowMark Colorado Holdings LLC now owns 2,723,715 shares of the medical device company's stock valued at $98,108,000 after acquiring an additional 337,026 shares during the last quarter. GW&K Investment Management LLC grew its stake in Tandem Diabetes Care by 18.0% in the 4th quarter. GW&K Investment Management LLC now owns 2,123,488 shares of the medical device company's stock valued at $76,488,000 after acquiring an additional 323,674 shares during the last quarter. Park West Asset Management LLC grew its stake in Tandem Diabetes Care by 49.5% in the 4th quarter. Park West Asset Management LLC now owns 1,600,000 shares of the medical device company's stock valued at $57,632,000 after acquiring an additional 530,000 shares during the last quarter. Finally, Stephens Investment Management Group LLC grew its stake in Tandem Diabetes Care by 22.1% in the 4th quarter. Stephens Investment Management Group LLC now owns 1,555,809 shares of the medical device company's stock valued at $56,040,000 after acquiring an additional 281,327 shares during the last quarter.

Insider Activity at Tandem Diabetes Care

In related news, COO Jean-Claude Kyrillos acquired 10,538 shares of the business's stock in a transaction that occurred on Friday, March 7th. The shares were acquired at an average cost of $18.12 per share, for a total transaction of $190,948.56. Following the completion of the purchase, the chief operating officer now directly owns 10,538 shares in the company, valued at $190,948.56. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 1.90% of the company's stock.

Tandem Diabetes Care Trading Up 1.7%

Shares of TNDM stock traded up $0.38 during trading hours on Monday, hitting $23.36. 1,250,673 shares of the company were exchanged, compared to its average volume of 1,497,256. Tandem Diabetes Care, Inc. has a 1 year low of $15.75 and a 1 year high of $53.69. The firm has a fifty day moving average of $18.66 and a 200 day moving average of $28.14. The company has a quick ratio of 2.32, a current ratio of 2.90 and a debt-to-equity ratio of 1.29. The firm has a market cap of $1.56 billion, a PE ratio of -12.12 and a beta of 1.47.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last released its quarterly earnings results on Wednesday, April 30th. The medical device company reported ($0.67) earnings per share for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.07). Tandem Diabetes Care had a negative return on equity of 44.19% and a negative net margin of 14.84%. The company had revenue of $234.42 million for the quarter, compared to analyst estimates of $220.19 million. During the same period in the previous year, the business posted ($0.65) EPS. The firm's quarterly revenue was up 22.3% compared to the same quarter last year. Analysts expect that Tandem Diabetes Care, Inc. will post -1.68 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages recently commented on TNDM. Canaccord Genuity Group increased their price objective on shares of Tandem Diabetes Care from $58.00 to $59.00 and gave the company a "buy" rating in a research note on Thursday, May 1st. Mizuho assumed coverage on shares of Tandem Diabetes Care in a research note on Thursday, April 10th. They issued a "neutral" rating and a $20.00 price objective on the stock. Stifel Nicolaus reduced their target price on shares of Tandem Diabetes Care from $60.00 to $31.00 and set a "buy" rating on the stock in a report on Thursday, May 1st. Sanford C. Bernstein lowered shares of Tandem Diabetes Care from an "outperform" rating to a "market perform" rating and reduced their target price for the company from $35.00 to $25.00 in a report on Friday, February 28th. Finally, Morgan Stanley lowered shares of Tandem Diabetes Care from an "overweight" rating to an "equal weight" rating and reduced their target price for the company from $45.00 to $22.00 in a report on Wednesday, March 5th. Eight equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $39.81.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.